NCT01019070View on ClinicalTrials.gov

Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Hepatic Insufficiency
Interventions
DRUG

BMS-650032

Capsules, Oral, 200 mg, BID, 7 Days

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

92801

Advanced Clinical Res Inst, Anaheim

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY